Zydus Lifesciences has revised its ongoing share buyback programme by increasing the buyback price and reducing the number of shares on offer, the company announced on Wednesday, according to livemint.com. The buyback price was raised to ₹1,150 per share, while the total number of equity shares to be repurchased was cut.
Earlier in May, Zydus Lifesciences had approved a share buyback worth ₹1,100 crore, authorizing the repurchase of up to 95.65 lakh equity shares via the tender offer route. The buyback committee’s recent decision to increase the price per share and reduce the quantity reflects adjustments to the initial terms of the programme, as detailed by livemint.com.
Share buybacks are a common strategy for companies to return value to shareholders and optimize capital structure. Zydus Lifesciences’ move to raise the buyback price may signal confidence in its stock valuation and a desire to attract more shareholder participation. The ₹1,100 crore buyback is significant in the pharmaceutical sector, where companies often use buybacks to manage share dilution and improve earnings per share.
Zydus Lifesciences is expected to continue executing the revised buyback plan in the near term. Investors will watch for updates on the completion timeline and the final number of shares repurchased. The company’s next disclosures will clarify the impact of the buyback on its share capital and financial metrics, according to livemint.com.